WO1998030891A1 - Implantable sensor employing an auxiliary electrode - Google Patents
Implantable sensor employing an auxiliary electrode Download PDFInfo
- Publication number
- WO1998030891A1 WO1998030891A1 PCT/US1997/024119 US9724119W WO9830891A1 WO 1998030891 A1 WO1998030891 A1 WO 1998030891A1 US 9724119 W US9724119 W US 9724119W WO 9830891 A1 WO9830891 A1 WO 9830891A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- electrode
- sensor
- reference electrode
- case
- enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/817—Enzyme or microbe electrode
Definitions
- the present invention relates to implantable electrochemical sensors and, more particularly to an implantable sensor that utilizes a biocompatible electroconductive case as an auxiliary electrode in a three electrode system.
- a typical two electrode electrochemical cell comprises an anode, otherwise known as the measuring electrode, and a cathode, otherwise known as the reference electrode.
- the quantity of hydrogen peroxide produced in the reaction of Equation 1 will be a direct measure of the glucose concentration.
- the hydrogen peroxide is detected as it is reoxidized at the measuring electrode which is maintained at a sufficient positive potential to carry out the following reaction (equation 2):
- Glucose detection is dependent upon the measurement of electrons removed from hydrogen peroxide in equation (2).
- the electrode is normally formed from a noble metal such as gold or platinum.
- the magnitude of the current flow for the oxidation of hydrogen peroxide at the measuring electrode must be equal to and balanced by an equivalent flow of current of the opposite sign at the reference electrode.
- the reference electrode potential is a function of the concentration of the silver chloride. If the amount of current flowing through the reference electrode is sufficiently large that the Ag metal or the AgCl solid is exhaustively consumed the potential for the reference electrode will not be constant. As a result, there is a need for a system that limits the amount of the current through the reference electrode such that the Ag metal or AgCl solid is not exhaustively consumed and instability in the reference electrode's potential does not result.
- U.S. Patent No. 5,352,348 to Young et al. discloses a glucose sensor that employs a measuring electrode, a silver electrode and a silver/silver chloride electrode.
- the present invention provides an implantable sensor that provides stable reference electrode potential during operation.
- the implantable sensor comprises a biocompatible electroconductive housing, which functions as an auxiliary electrode, in which a measuring electrode, a reference electrode, a voltage source and an electronic circuit for measuring the measuring electrode's response are housed.
- the auxiliary electrode reduces the consumption of Ag metal and AgCl solid by reducing the magnitude of the current flowing through the reference electrode and thereby stabilizes the electrode potential. Accordingly, it is an object of the present invention to provide an implantable sensor that is capable of correcting and preventing instability in the reference electrode's potential during operation.
- Fig. 1 is a circuit diagram of a typical two electrode electrochemical cell and potentiostat
- Fig. 2 is a circuit diagram of a three electrode electrochemical cell and potentiostat system in accordance with the present invention
- Fig. 3 is an exploded view of an implantable glucose sensor device employing the three electrode electrochemical cell and potentiostat of the present invention
- Fig. 4 is an exploded view of a schematic diagram of a glucose sensor employing an enzyme-containing membrane in accordance with the present invention.
- Fig. 5 is a schematic representation of a portion of an enzyme-containing membrane in accordance with the present invention.
- Fig. 1 is a circuit diagram of a typical two electrode amperometric electrochemical cell and potentiostat.
- the two electrode electrochemical cell and potentiostat includes a measuring electrode 10 and a reference electrode 12, preferably a silver electrode and more preferably a Ag/AgCl electrode.
- the measuring electrode 10 is a platinum anode, which is in contact with an ionically conductive solution 13, for example aqueous, non-aqueous or body fluids.
- the voltage source 14 is an adjustable voltage source such as a battery and voltage regulating circuit. The voltage source is set to maintain the measuring electrode 10 at a desired potential. In the case of the oxidation of hydrogen peroxide, this potential is of a positive value greater than 0.500 volts, but does not exceed +0.700 volts. This applied potential is versus the reference electrode 12, which is also in physical contact with the ionically conductive solution 13.
- the hydrogen peroxide gives up electrons to the measuring electrode 10 in the oxidation step. These electrons travel from the measuring electrode 10, via an electronic conductor, generally designated 15, to the reference electrode 12 where they complete the circuit as they are returned to the solution 13 via the reduction of the AgCl solid. As these electrons pass through the conductor, they are measured by an ammeter 16, which allows one to measure the electroactive analyte, hydrogen peroxide. The voltage difference between the measuring and reference electrodes 10 and 12, respectively, is measured by a voltmeter 17.
- a third or auxiliary electrode takes the place of the reference electrode in returning the bulk of the current to the aqueous solution.
- the reference electrode is still in contact with the aqueous solution and a potentiostat senses the electrical potential of this electrode relative to the solution and fixes the auxiliary electrode at a potential so that the auxiliary electrode can act as a "surrogate" for the reference electrode. Because very little current flows through the reference electrode in this arrangement, the reference electrode is not exhausted and a stable reference electrode potential can be maintained.
- the three electrode electrochemical cell and potentiostat includes a measuring electrode 18, which is preferably a platinum anode, a reference electrode 20, which is preferably a silver electrode and, more preferably a Ag/AgCl electrode, and an auxiliary electrode 22. All three electrodes are in contact with an ionically conductive solution 23, for example aqueous, non-aqueous or body fluids.
- a potentiometer 24 measures the electrical potential between the measuring electrode 18 and the reference electrode 20.
- the electrical potential of the auxiliary electrode 22 is established by the variable voltage source 26.
- the voltage difference between the auxiliary electrode 22 and the measuring electrode 18 is measured by a voltmeter 28.
- the operation of the three electrode electrochemical cell and potentiostat is as follows.
- a certain potential difference between the measuring electrode 18 and the reference electrode 20 is desired, therefore, the variable voltage source 26, is adjusted until the desired potential difference between the measuring electrode 18 and the reference electrode 20 is established.
- This potential difference is measured by the potentiometer 24.
- the magnitude of the current observed for that potential difference between the measuring electrode 18 and the reference electrode 20 is measured by an ammeter 30.
- the measured current is proportional to the concentration of the electroactive analyte.
- One advantage of an auxiliary electrode is that the amount of current flow between the measuring electrode and the reference electrode in a three electrode system is very small, typically ten orders of magnitude smaller than the current through the measuring electrode and reference electrode in a two electrode system.
- an implantable sensor such as a glucose sensor, generally designated 32, in accordance with the present invention may be disc shaped, although many other configurations are also possible.
- the sensor 32 comprises a measuring electrode 34, a reference electrode 36, an auxiliary electrode, generally designated 38, and an electrical circuit 40 for measuring the response of the measuring electrode 34.
- the measuring electrode 34, reference electrode 36 and auxiliary electrode 38 are not in direct electrical contact with one another. However, it is desirable that the measuring electrode 34, reference electrode 36 and auxiliary electrode 38 form an electric circuit when they contact the ionically conductive solution.
- the auxiliary electrode 38 is a case 42 made from a suitable electroconductive biocompatible material, preferably a metal.
- the case 42 must be made from an electroconductive material so that it can function as the auxiliary electrode 38 within the sensor 32.
- the preferred electroconductive material is titanium because of its excellent biocompatibility characteristics, its strength and its relatively low cost. Titanium metal is known to possess excellent biocompatibility characteristics with regard to living body tissues. As a result, titanium metal has been frequently used for implants, such as bone, dental and heart pacemakers. Examples of other materials that can be used for the case are graphite/epoxy composite, stainless steel, silver, gold, platinum, and titanium alloys, such as nickel-titanium or nickel-titanium-copper.
- the case may be coated with a bicompatible coating of hydroxyapatite or be electrochemically coated with an oxide or carbide coating both of which processes are known in the art.
- the case 42 has a large surface area so that the current density of the auxiliary electrode 38 is small. By minimizing the current density of the auxiliary electrode 38, the damage to the living tissue surrounding the implantable sensor 32 can be minimized.
- the surface area of the case 42 can be in the range of about 10 cm 2 to about 60 cm 2 , preferably in the range of about 15 cm 2 to about 45 cm 2 . It is additionally desirable that the case 42 is chemically inert or unreactive.
- the case 42 includes a first port 44 in which the reference electrode 36 is mounted and a second port 46 in which the measuring electrode 34 is mounted.
- the reference electrode 36 is preferably a silver or silver/silver chloride reference electrode.
- the measuring electrode 34 is preferably a noble metal anode, more preferably a platinum anode.
- the area occupied by the first port 44 is small about 0.1 cm 2 to 0.4 cm 2 .
- the area occupied by the second port 46 is small about 0.1 cm 2 to 0.4 cm 2 .
- the reference and measuring electrodes 36 and 34 are sealed to the case 42 via O-rings, generally designated 47.
- the case 42 may comprise a port that contains both the reference electrode 36 and the measuring electrode 34 so long as the reference electrode 36 and measuring electrode 34 are not in direct electrical contact (i.e., a short circuit) with one another or with the auxiliary electrode 38.
- the case 42 further comprises a compartment 48 that is shaped to receive the electronic circuit 40, for example a circuit board.
- a lid, generally designated 50 is used to seal the electronic circuit 40 within the case 42 via an O-ring, generally designated 51.
- the lid 50 can be either a resealable lid 52 or welded into place (not shown).
- the electronic circuit 40 includes means for transmitting a signal to a receiver located outside the body. Any suitable means for transmitting a signal to a receiver located outside the body can be used.
- a miniature power supply such as a lithium battery, and microelectronics for transmitting a measured signal to a receiver outside of the human body can be used.
- Transmission of data can be by means of radio waves, sound waves or even by means of modulated light.
- Examples of other communication/transmitting means are described in U.S. Patent No. 4,941,201 to Davis and U.S. Patent No. 5,260,701 to Guern et al., which are incorporated herein by reference. Those skilled in the art will appreciate that other suitable communication means are within the scope of the present invention.
- the senor 32 is implanted beneath the surface of the skin with the second port 46 and the measuring electrode 34 facing towards the underlying layer of muscle. This position allows ready access to the unit for repair or replacement.
- the sensor 32 can also be implanted so that the second port 46 and measuring electrode 34 face the peritoneal cavity. It is relatively important that the sensor 32 not be directly in contact with the circulatory system so that formation of blood clots does not interfere with the operation. While anticoagulants can be used to prevent clot formation, unless the patient requires anticoagulative therapy for some other reason, it is probably not prudent to require anticoagulation simply for an implantable sensor device.
- a successful implantable sensor must make accurate measurements over a prolonged period of time and must be biologically compatible, i.e., not induce attempts by the body to reject the implants.
- biological compatibility is not an extremely serious problem for a housing of the sensor device.
- Implants made of a biocompatible material usually become surrounded by a layer of fibroblasts, but there are generally no episodes of rejection.
- a number of well-known biologically compatible materials are suitable for fabrication of implantable devices. For example, small implants machined from titanium are easily polished and are well accepted by the human body. A wide range of plastic materials such as teflon are also biocompatible. For experimental purposes more easily machinable materials such as 405 stainless steel may be preferable to titanium and are also well tolerated.
- titanium to encase the implantable device of the present invention.
- the titanium surface can be used as an auxiliary or third electrode for the detection system with the electronics within the case connected so as to maintain the measuring electrode at a constant potential relative to the reference electrode.
- the use of an auxiliary electrode allows the amperometric current to be carried by the case and, thus, be spread over a large area so that the current density is very low and will cause no biological effects.
- blood glucose measurements can be used to effect calibration. If the patient takes a series of blood glucose measurements over time, these can be plotted against sensor output to develop a time constant for sensor response. Thereafter, blood glucose measurements can be used to automatically calibrate or adjust the implanted sensor.
- the device of the present invention is preferably implanted in a site away from direct blood circulation to avoid clotting problems, leukocytes will migrate out of the circulatory system to congregate around any "foreign" body. This leukocyte accumulation may damage the membrane or compromise the accuracy of the glucose readings.
- an anti-inflammatory, anti-leukocyte compound into the enzyme mixture.
- hydrocortisone or similar cortical steroids such as cortisone and prednisolone, at about 0.1 to 1.0% by weight. These steroids can be dispersed in the aqueous phase of the enzyme mixture where they gradually dissolve and very slowly diffuse out through the outer membrane keep the surrounding area free from attack by leukocytes.
- the measuring electrode 34 includes an enzyme-containing membrane having a semi-interpenetrating polymer network of fibrillated polytetrafluoroethylene and a silicon compound, wherein the network is infiltrated with an enzyme, preferably glucose oxidase.
- an enzyme-containing membrane is described in U.S. Patent Application No. 08/769,863, filed on December 19, 1996, (Attorney Docket No. 594936.002), which is incorporated herein by reference.
- Fig. 4 illustrates one embodiment of the invention in which a glucose sensor employs an outer membrane 56 and an enzyme-containing membrane 58, and a measuring electrode 60.
- the enzyme-containing membrane 58 is disposed between the outer membrane 56 and the electrode 60.
- the measuring electrode can be any suitable electrode that is capable of detecting and measuring hydrogen peroxide.
- the electrode is a noble metal electrode, more preferably a platinum electrode. It is desirable that the surface of the electrode 60 is maintained electro-active to maximize the effectiveness of the glucose sensor.
- the concentration of oxygen at the site of glucose oxidation must be greater than or equal to the glucose concentration at the site of glucose oxidation such that the glucose is the limiting factor in the oxidation reaction rather than the oxygen.
- the glucose concentration must be restricted and oxygen transport to the site of glucose oxidation must be enhanced.
- glucose and oxygen contained within the body tissues of a subject come into contact with the outer membrane 56 of the glucose sensor 54.
- the outer membrane 56 provides greater restriction to glucose than to oxygen and thus, reduces the concentration of glucose flowing through the outer membrane 56.
- the function of the outer membrane 56 is to affect the concentrations of glucose and oxygen such that after the glucose and oxygen have passed through the outer membrane 56, the concentration of oxygen is preferably greater than or equal to the concentration of glucose. By doing so, the outer membrane 56 establishes the stoichiometric relationship required for the glucose oxidation reaction.
- this stoichiometric relationship must be maintained at the sites of glucose oxidation, namely the enzymes contained within the enzyme-containing membrane 58. Maintaining this stoichiometric relationship at the enzymes is facilitated by the semi- interpenetrating polymer network and its enhancing effects on oxygen transport. Furthermore, the enzyme-containing membrane 58 creates a tortuous path for the glucose in its attempt to pass through the membrane, however, it does not restrict the flow of glucose to the enzymes. This added restrictive control on glucose and the enhanced oxygen transport to the enzymes, such that localized concentrations of oxygen are formed, insures that the stoichiometric relationship is maintained at the enzymes.
- the concentration of oxygen at the enzyme is greater than or equal to the concentration of glucose at the enzyme.
- oxygen does not act as the limiting factor in the glucose oxidation reaction.
- the hydrogen peroxide generated during the glucose oxidation corresponds to the glucose present at the enzyme.
- Current flow representative of oxidation of hydrogen peroxide at the anode must be measured relative to a reference electrode so that a complete circuit is formed.
- the reference electrode is commonly provided by a silver or silver/silver chloride electrode in electrical contact with the body fluids.
- the outer membrane 56 is preferably a polycarbonate but may be made of any other suitable solid porous or permeable material.
- the outer membrane reduces the rate of mass transport of the glucose through the membrane and yet does not interfere with the rate of mass transport of the oxygen through the membrane.
- the outer membrane 56 provides the restrictive control for the glucose.
- the outer membrane 56 also prevents catalase, an enzyme that destroys hydrogen peroxide, and other large molecules from passing through the membrane.
- the pore size and thickness of the outer membrane are selected to insure that the passage of glucose through the outer membrane is sufficiently hindered in comparison to the passage of oxygen. In general, the thicker the membrane and the smaller the pore size, the more the passage of glucose will be hindered. In implantable glucose sensors, the outer membrane 56 must be made from a suitable biocompatible material.
- a membrane which is useful as the outer membrane 56 and which is commercially available is a polycarbonate membrane available from Poretics Corp. of Livermore, California. This membrane is available and employed in pore sizes of about .01 to .1 micron and pore densities of about 4 x 10 8 to 6 x 10 8 .
- the enzyme-containing membrane 58 comprises a semi- interpenetrating polymer network, made of fibrillated polytetrafluoroethylene (PTFE) and a silicon compound.
- PTFE polytetrafluoroethylene
- This membrane is commercially available and a method for making this membrane is described in U.S. Patent Nos. 4,945,125 and 4,832,009, and Dillon, Silicone and Polytetrafluoroethylene) Interpenetrating Networks, 1994, p. 393, which are incorporated herein by reference.
- the membrane can range in thickness from about 5 to 50 ⁇ .
- the membrane typically contains about 10 to 40% by volume of the silicon compound or elastomer.
- the porosity of the enzyme- containing membrane is from about 25 % to about 55 % .
- the term "semi-interpenetrating polymer network" is used herein to refer to membranes prepared by the methods described in either of the aforementioned patents to Dillon and their functional equivalents.
- the method for making the semi-interpenetrating polymer network as described in U.S. Patent No. 4,945,125 comprises the steps of: (1) intimately blending a mixture of a major amount of unsintered and unfibrillated particulate polytetrafluoroethylene dispersion resin (commercially available from E.I.
- du Pont de Nemours & Co., Inc. under the designations TEFLON * 6 and 6C and by Imperial Chemical Industries as FLUON ® CD1, CD 123 and CD525) and minor amounts of (A) a hydrocarbon liquid and (B) an addition curable silicone composition consisting essentially of a polydiorganosiloxane having alkenyl unsaturation, an organohydrogenpolysiloxane crosslinking agent, a catalyst for promoting crosslinking of the polysiloxane, and an inhibitor for the catalytic reaction; (2) forming the blend into an extrudable shape; (3) biaxially extruding the blend through a die into a shaped extrudate product having a randomly fibrillated structure; and (4) evaporating the hydrocarbon liquid, and activating the catalyst so as to generate a cured silicone elastomer and polytetrafluoroethylene semi-interpenetrating polymer network comprising the fibrillated extrudate structure.
- Another method for making a semi-interpenetrating polymer network as described in U.S. Patent No. 4,832,009 comprises the steps of: (1) blending polyorganosiloxane (commercially available from Dow Corning Corporation under the name SILASTIC ® MDX4- 4210) with a catalyst for promoting crosslinking of the polysiloxane in a 10:1 ratio; (2) mixing the blend with kerosene (commercially available from Fisher Scientific); and (3) applying the mixture to a substrate of expanded polytetrafluoroethylene film (commercially available from Tetratec Corporation of Feasterville, Pennsylvania) by means of a spray apparatus.
- polyorganosiloxane commercially available from Dow Corning Corporation under the name SILASTIC ® MDX4- 4210
- kerosene commercially available from Fisher Scientific
- a substrate of expanded polytetrafluoroethylene film commercially available from Tetratec Corporation of Feasterville, Pennsylvania
- the silicon compound in the semi-interpenetrating polymer network is a cross-linked polyorganosiloxane, more preferably polydimethylsiloxane.
- the silicon compound facilitates the transport of oxygen to the sites of glucose oxidation.
- the semi- interpenetrating polymer network of fibrillated PTFE provides a porous membrane. The porosity of the membrane makes it possible to infiltrate it with the enzyme thus forming the enzyme-containing membrane 58, Fig. 4, a portion of which is represented by the schematic representation in Fig. 5.
- the semi-interpenetrating network generally designated 59, is a network of nodes 57 and fibrils 61 infiltrated with the enzyme 62.
- the semi-interpenetrating polymer network To facilitate the infiltration of the enzyme into the semi-interpenetrating network, it is desirable to treat the semi-interpenetrating polymer network with a surfactant.
- the surfactant renders the membrane hydrophilic.
- the surfactant is a nonionic surfactant, more preferably, methyl terminated poly(dimethylsiloxane-b-ethylene oxide).
- other surfactants can be used and especially surfactants with a silicon moiety and a hydrophilic moiety.
- the enzyme is free from catalase activity, has a relatively long life, is very active and is a pure concentrate to maximize the effectiveness of the glucose sensor.
- the enzyme is an oxidase, more preferably glucose oxidase (E.C. 1.1.3.4).
- Other useful enzymes have already been mentioned. It is also within the scope of the invention to use more complex systems employing a combination of enzymes. For example, enzyme systems are known in which a first enzyme reacts with an analyte to provide an intermediate which reacts with a second enzyme to produce the chemical species that is detected at the electrode.
- the speed of oxygen diffusion through a barrier is controlled by the thickness of the barrier and by the amount of oxygen that can dissolve through a unit thickness of the barrier. That is, making the barrier thinner, i.e., bringing the analyte containing fluid closer, or making the barrier dissolve more oxygen will increase the rate of oxygen diffusion. Therefore, the enzyme-containing membrane 58 should be made as thin as feasible to maximize the rate of oxygen movement into the glucose sensor 54.
- the enzyme can be immobilized within the interpenetrating network using a number of techniques.
- the enzyme is mixed with other proteins and crosslinked to form an enzyme gel as described below.
- other immobilization techniques may also be useful.
- the silicon compound could be functionalized such that the enzyme could be covalently linked to the interpenetrating network.
- the enzyme can also be compounded with matrix formers, such as polymers, film-formeres or binders.
- a carrier protein such as an albumin, i.e., bovine serum albumin (BSA), and human albumin, or gelatin
- BSA bovine serum albumin
- human albumin or gelatin
- the enzyme concentration will vary depending upon the activity of the enzyme.
- Glucose oxidase is dissolved in the mixture at about 5 to 50% by weight.
- Amounts of alternative enzymes can be determined empirically based upon the activity of the particular enzyme.
- the enzyme mixture is applied to the semi-interpenetrating network and uniformly infiltrated into the semi-interpenetrating network by gently spreading the enzyme mixture on the membrane and rubbing with a smooth blunt spatula, thus resulting in an enzyme-containing membrane.
- Glutaraldehyde/acetate buffer is applied to the semi- interpenetrating network after the enzyme has been applied to crosslink the enzyme.
- An alternative method may be used for infiltration of the enzyme into the semi- interpenetrating polymer network if the stabilized gel is to be based on a cross-linked protein gel.
- a suitable soluble carrier protein such as an albumin, i.e. , bovine serum albumin (BSA), and human albumin, or gelatin, at about 1 to 15% by weight final concentration is dissolved in a suitable buffer such as 0.2 M sodium acetate buffer, and an enzyme such as glucose oxidase is dissolved in the mixture at about 1 % to 5 % by weight final concentration.
- a suitable soluble carrier protein such as an albumin, i.e. , bovine serum albumin (BSA), and human albumin, or gelatin
- BSA bovine serum albumin
- glucose oxidase is dissolved in the mixture at about 1 % to 5 % by weight final concentration.
- Sufficient purified glutaraldehyde as an aqueous 2.5% solution is added to dilute the protein solution to the correct final
- the final glutaraldehyde concentration following dilution is preferably between 0.1 and 1 % and more preferably about 0.6% .
- This mixture is swirled briefly to mix and is then poured onto the membrane supported on glass plate and spread with a glass rod. Within a few hours a uniform layer of enzyme gel is formed. This gel is stored in a humidified atmosphere to prevent dehydration of the gel.
- the incorporation of the novel enzyme-containing membrane into the glucose sensor of the present invention provides a glucose sensor that accurately measures glucose levels in extremely low oxygen environments such as 2% oxygen.
- the enzyme-containing membrane shows no decrease in response for at least about 2Vz months. In fact, the enzyme- containing membrane's performance has been observed to improve as it ages.
- the glucose sensor of the present invention comprises a measuring electrode, preferably a platinum anode, that is in contact with an aqueous fluid to be measured, e.g., the glucose- containing solution.
- a voltage source maintains the measuring electrode at a proper potential (here a positive potential to oxidize hydrogen peroxide).
- a reference electrode is also in contact with the glucose solution. The electrons removed from hydrogen peroxide at the measuring electrode flow through a conductor to the reference electrode where they complete the circuit by being returned to the aqueous solution. As the electrons pass through the conductor they are measured by an ammeter thus allowing the hydrogen peroxide to be quantitated.
- the present invention seals all of the electrical components in a small implantable package. In this case it is absolutely essential that the seal be water tight to avoid current leaks and to avoid water damage to the electronics.
- An additional problem with implanted electrodes is that a significant current flow through the reference electrode often results in electrochemical side reactions that can damage a silver electrode and may also be toxic to the living tissue around the device.
- a third or auxiliary electrode usually of a larger area and non-reactive material, takes the place of the reference electrode in returning the bulk of the current to the aqueous solution.
- the reference electrode is still in contact with the aqueous solution and a potentiostat senses the electrical potential of this electrode relative to the solution and fixes the auxiliary electrode at this potential so that the auxiliary electrode can act as a "surrogate" for the reference electrode. Because very little current flows through the reference electrode in this arrangement, there are no side reactions to damage the reference electrode or the surrounding living tissue.
- a subject's glucose level can be determined by using the glucose sensor of the present invention by situating the glucose sensor within the subject and calculating the glucose level from the measuring electrode's response.
- the glucose level of a sample of blood from a subject can be determined by using the glucose sensor of the present invention and calculating the glucose level from the measuring electrode's response.
- microbes may directly destroy the glucose metabolizing enzyme, it is also likely for them to disrupt the glucose measurement by producing catalase or peroxidases which consumes the hydrogen peroxide before it can react with the electrode surface.
- antifungals or wide spectrum antibiotics into the enzyme mixture will largely prevent microbial interference.
- gentamicin and/or penicillin, at about 0.1 to 0.8% percent by weight, and/or other broad spectrum antibiotics can be incorporated into the enzyme mixture to prevent bacterial interference.
- the outer membrane 56 is generally believed to protect the glucose oxidase from various proteases. However, in the experiments leading to the present invention, it was discovered that stabilized glucose oxidase is not readily attacked by the common proteolytic enzyme trypsin. Therefore, trypsin may be incorporated in the outer membrane as an antiproteolytic enzyme to help destroy other proteolytic enzymes that might be produced by microorganisms, etc.
- Stability of the enzyme mixture of the present invention can also be improved by the addition of antioxidants and/or free radical trapping agents.
- Vitamin E which is also an oxygen solvent, can be incorporated into the enzyme mixture as can any of a number of "preservatives" such as various parabens, BHT (butylated hydroxy toluene) and its analogs, and/or superoxide dismutase.
- a third membrane is situated between the enzyme-containing membrane and the electrode, i.e., so as to sandwich the enzyme containing membrane between the outer membrane and this third membrane.
- the function of the third membrane is to exclude compounds such as ascorbic acid and acetaminophen from interfering with the analysis.
- a cellulose acetate membrane can be used for this third membrane. See U.S. Patent 3,979,274 and 4,073,713 to Newman.
- polytetrafluoroethylene and polydimethylsiloxane semi- interpenetrating polymer network membranes also known as White Silon #320 (Bio Med Sciences, Inc.), were removed from their release liner, as membrane strips 2" by 3" and were rinsed with deionized water and ethanol. These membranes were stored in a bottle of sterilizing 70% Ethanol/deionized water, until they were used for enzyme studies. The membranes were removed from their storage bottle and placed on a 4" by 4" glass plate. The strips of membrane were stretched out on a glass plate and blotted dry. Then approximately, 10 to 20 drops of a nonionic surfactant, Dimethylsiloxane-ethylene oxide copolymer, 20 cs.
- a nonionic surfactant Dimethylsiloxane-ethylene oxide copolymer
- a 2.5 ml aliquot of this 2.5% Glutaraldehyde/acetate buffer is removed and set aside for use later in crosslinking the enzyme gel in the pores of the modified White Silon #320 membrane.
- About 2.5 ml of the Glucose Oxidase/Bovine Serum Albumin solution is placed on the modified White Silon #320 membrane (one of the 2" by 3 " strips of membrane on a glass plate) via a pipette.
- the membrane prepared as described above was very elastic and flexible, so long as it was wet. If the membrane was allowed to dry out it would become very brittle. However, with the addition of a water(buffer) the membrane became elastic once again. This drying out and rehydration cycle seems to be totally reversible, in that no loss of enzyme activity is noted. Also, there is no observable degradation of the mechanical properties for this enzyme embedded membrane.
- the thickness of membranes produced by the above procedure was in the range of from about 50 microns to 65 microns.
- a glucose sensor in accordance with the present invention was prepared by punching a small disc (a #16 needle, about 0.1 mm) of the enzyme-containing membrane, prepared in Example 1 above. This disc is placed in a small vial with a milliliter of Gomori buffer. An electrode collar is solvent glued (methylene chloride) to an outer membrane made of polycarbonate. This assembly was set aside to dry, with the outer membrane lying on the bottom. After about 30 minutes, a small drop of Gomori buffer was placed in the "well” of the electrode collar. The small disc of enzyme-containing membrane was placed in the well and allowed to settle to the bottom of the well.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59045/98A AU734003B2 (en) | 1997-01-06 | 1997-12-31 | Implantable sensor employing an auxiliary electrode |
JP53094598A JP3950174B2 (en) | 1997-01-06 | 1997-12-31 | Glucose sensor |
EP97954646A EP1021706A4 (en) | 1997-01-06 | 1997-12-31 | Implantable sensor employing an auxiliary electrode |
CA002276069A CA2276069C (en) | 1997-01-06 | 1997-12-31 | Implantable sensor employing an auxiliary electrode |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/779,304 US5914026A (en) | 1997-01-06 | 1997-01-06 | Implantable sensor employing an auxiliary electrode |
US08/779,304 | 1997-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998030891A1 true WO1998030891A1 (en) | 1998-07-16 |
Family
ID=25115970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/024119 WO1998030891A1 (en) | 1997-01-06 | 1997-12-31 | Implantable sensor employing an auxiliary electrode |
Country Status (6)
Country | Link |
---|---|
US (1) | US5914026A (en) |
EP (1) | EP1021706A4 (en) |
JP (1) | JP3950174B2 (en) |
AU (1) | AU734003B2 (en) |
CA (1) | CA2276069C (en) |
WO (1) | WO1998030891A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059373A1 (en) * | 1999-04-07 | 2000-10-12 | Spectrx, Inc. | Assay device for measuring characteristics of a fluid on a continual basis |
US8909314B2 (en) | 2003-07-25 | 2014-12-09 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US9131885B2 (en) | 2009-07-02 | 2015-09-15 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
US9351677B2 (en) | 2009-07-02 | 2016-05-31 | Dexcom, Inc. | Analyte sensor with increased reference capacity |
US9357951B2 (en) | 2009-09-30 | 2016-06-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JP3348528B2 (en) * | 1994-07-20 | 2002-11-20 | 富士通株式会社 | Method for manufacturing semiconductor device, method for manufacturing semiconductor device and electronic circuit device, and electronic circuit device |
US7657297B2 (en) * | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6134461A (en) * | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
WO2000030698A1 (en) | 1998-11-20 | 2000-06-02 | University Of Connecticut | Apparatus and method for control of tissue/implant interactions |
US6343225B1 (en) * | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
US6488828B1 (en) * | 2000-07-20 | 2002-12-03 | Roche Diagnostics Corporation | Recloseable biosensor |
US8372139B2 (en) | 2001-02-14 | 2013-02-12 | Advanced Bio Prosthetic Surfaces, Ltd. | In vivo sensor and method of making same |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
AU2002309528A1 (en) | 2001-04-02 | 2002-10-15 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6613379B2 (en) | 2001-05-08 | 2003-09-02 | Isense Corp. | Implantable analyte sensor |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6923936B2 (en) * | 2001-10-23 | 2005-08-02 | Medtronic Minimed, Inc. | Sterile device and method for producing same |
US6952604B2 (en) * | 2001-12-21 | 2005-10-04 | Becton, Dickinson And Company | Minimally-invasive system and method for monitoring analyte levels |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US9492111B2 (en) * | 2002-04-22 | 2016-11-15 | Medtronic Minimed, Inc. | Methods and materials for stabilizing analyte sensors |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7312197B2 (en) * | 2003-02-24 | 2007-12-25 | University Of Maryland, Baltimore | Method of modifying glucose activity using polypeptides selectively expressed in fat tissue |
US7134999B2 (en) * | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US7473548B2 (en) * | 2003-04-25 | 2009-01-06 | Medtronic, Inc. | Optical detector for enzyme activation |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
WO2005019795A2 (en) * | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US7460898B2 (en) * | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US20050176136A1 (en) * | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7366556B2 (en) | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2007120442A2 (en) * | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP1649260A4 (en) | 2003-07-25 | 2010-07-07 | Dexcom Inc | Electrode systems for electrochemical sensors |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7467003B2 (en) * | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7933639B2 (en) | 2003-08-01 | 2011-04-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
KR20050055202A (en) * | 2003-12-05 | 2005-06-13 | 한국전자통신연구원 | Micro reference electrode of implantable continuous biosensor using iridium oxide, manufacturing method thereof, and implantable continuous biosensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7699964B2 (en) * | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
WO2009048462A1 (en) | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) * | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US7241266B2 (en) * | 2004-05-20 | 2007-07-10 | Digital Angel Corporation | Transducer for embedded bio-sensor using body energy as a power source |
US7713574B2 (en) | 2004-07-13 | 2010-05-11 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US20080242961A1 (en) * | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7468033B2 (en) * | 2004-09-08 | 2008-12-23 | Medtronic Minimed, Inc. | Blood contacting sensor |
EP1802962B1 (en) * | 2004-10-12 | 2018-06-06 | Ascensia Diabetes Care Holdings AG | Concentration determination in a diffusion barrier layer |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
WO2006110193A2 (en) * | 2005-04-08 | 2006-10-19 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US20060252027A1 (en) * | 2005-05-05 | 2006-11-09 | Petisce James R | Cellulosic-based resistance domain for an analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
CN102440785A (en) | 2005-08-31 | 2012-05-09 | 弗吉尼亚大学专利基金委员会 | Sensor signal processing method and sensor signal processing device |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
EP2004796B1 (en) * | 2006-01-18 | 2015-04-08 | DexCom, Inc. | Membranes for an analyte sensor |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US9339217B2 (en) | 2011-11-25 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US20080064937A1 (en) | 2006-06-07 | 2008-03-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
JP4836699B2 (en) | 2006-07-20 | 2011-12-14 | 株式会社東芝 | Optical glucose sensor chip and manufacturing method thereof |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
CN102772212A (en) | 2006-10-26 | 2012-11-14 | 雅培糖尿病护理公司 | Method, device and system for detection of sensitivity decline in analyte sensors |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
CA2683863C (en) | 2007-04-14 | 2019-01-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
EP2146625B1 (en) | 2007-04-14 | 2019-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683959C (en) | 2007-04-14 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US20080306434A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US20100025238A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
US8700114B2 (en) | 2008-07-31 | 2014-04-15 | Medtronic Minmed, Inc. | Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US8983568B2 (en) | 2008-09-30 | 2015-03-17 | Abbott Diabetes Care Inc. | Analyte sensors comprising leveling agents |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
EP2410910A4 (en) | 2009-03-27 | 2014-10-15 | Dexcom Inc | Methods and systems for promoting glucose management |
US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Method and system for providing real time analyte sensor calibration with retrospective backfill |
LT3689237T (en) | 2009-07-23 | 2021-09-27 | Abbott Diabetes Care, Inc. | Method of manufacturing and system for continuous analyte measurement |
FI4070729T3 (en) | 2009-08-31 | 2024-06-04 | Abbott Diabetes Care Inc | Displays for a medical device |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP4324399A3 (en) | 2011-04-15 | 2024-05-15 | DexCom, Inc. | Advanced analyte sensor calibration and error detection |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
EP3089666B1 (en) | 2013-12-31 | 2020-08-19 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
EP3125761B1 (en) | 2014-03-30 | 2020-09-30 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
KR101637325B1 (en) * | 2015-02-09 | 2016-07-08 | 주식회사 에이엠피올 | Degradation prevention structure for vital reaction of in vivo implantable continuous glucose monitoring sensor |
KR101636781B1 (en) * | 2015-02-09 | 2016-07-07 | 주식회사 에이엠피올 | Intercellular fluid extraction structure for detecting glucose |
US11553883B2 (en) | 2015-07-10 | 2023-01-17 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
CN212438615U (en) | 2017-10-24 | 2021-02-02 | 德克斯康公司 | Wearable device |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US20230031279A1 (en) * | 2019-12-31 | 2023-02-02 | Myant Inc. | Conductive thermoplastic elastomer electrodes, and method of manufacturing such electrodes |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3979274A (en) | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4484987A (en) * | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4832009A (en) | 1987-12-23 | 1989-05-23 | Bio Med Sciences, Inc. | Semi-interpenetrating network polymer backsheet bandage |
US4941201A (en) | 1985-01-13 | 1990-07-10 | Abbott Laboratories | Electronic data storage and retrieval apparatus and method |
US4945125A (en) | 1987-01-05 | 1990-07-31 | Tetratec Corporation | Process of producing a fibrillated semi-interpenetrating polymer network of polytetrafluoroethylene and silicone elastomer and shaped products thereof |
US5260701A (en) | 1990-01-19 | 1993-11-09 | Societe Bertin & Cie | Bidirectional inductive transmission of data with slave station supplied by the master |
US5372133A (en) * | 1992-02-05 | 1994-12-13 | N.V. Nederlandsche Apparatenfabriek Nedap | Implantable biomedical sensor device, suitable in particular for measuring the concentration of glucose |
US5469846A (en) * | 1992-10-19 | 1995-11-28 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4098669A (en) * | 1976-03-31 | 1978-07-04 | Diamond Shamrock Technologies S.A. | Novel yttrium oxide electrodes and their uses |
US4401122A (en) * | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4458686A (en) * | 1979-08-02 | 1984-07-10 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US5030333A (en) * | 1984-09-13 | 1991-07-09 | Children's Hospital Medical Center | Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor |
US4680268A (en) * | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4994167A (en) * | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4757022A (en) * | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
DE3613997A1 (en) * | 1986-04-25 | 1987-10-29 | Sigri Gmbh | ANODE FOR ELECTROLYTIC PROCESSES |
US4703756A (en) * | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4871366A (en) * | 1986-05-27 | 1989-10-03 | Clemson University | Soft tissue implants for promoting tissue adhesion to same |
US5362553A (en) * | 1987-01-05 | 1994-11-08 | Tetratec Corporation | Microporous waterproof and moisture vapor permeable fabric |
US5066683A (en) * | 1987-01-05 | 1991-11-19 | Tetratec Corporation | Microporous waterproof and moisture vapor permeable structures, processes of manufacture and useful articles thereof |
US5157058A (en) * | 1987-01-05 | 1992-10-20 | Tetratec Corporation | Microporous waterproof and moisture vapor permeable structures, processes of manufacture and useful articles thereof |
US4931213A (en) * | 1987-01-23 | 1990-06-05 | Cass Richard B | Electrically-conductive titanium suboxides |
US5352348A (en) * | 1987-04-09 | 1994-10-04 | Nova Biomedical Corporation | Method of using enzyme electrode |
US4759828A (en) * | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4859383A (en) * | 1987-06-01 | 1989-08-22 | Bio Med Sciences, Inc. | Process of producing a composite macrostructure of organic and inorganic materials |
US4849285A (en) * | 1987-06-01 | 1989-07-18 | Bio Med Sciences, Inc. | Composite macrostructure of ceramic and organic biomaterials |
US4849205A (en) * | 1987-11-17 | 1989-07-18 | Kuochih Hong | Hydrogen storage hydride electrode materials |
DE68909105T2 (en) * | 1988-05-17 | 1994-04-07 | Mitsubishi Materials Corp | Nickel-based hydrogen storage alloy and rechargeable alkaline battery. |
US4938850A (en) * | 1988-09-26 | 1990-07-03 | Hughes Aircraft Company | Method for plating on titanium |
US5019140A (en) * | 1988-12-21 | 1991-05-28 | W. L. Gore & Associates, Inc. | Irradiated expanded polytetrafluoroethylene composites, and devices using them, and processes for making them |
US5205921A (en) * | 1991-02-04 | 1993-04-27 | Queen's University At Kingston | Method for depositing bioactive coatings on conductive substrates |
US5322063A (en) * | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5399250A (en) * | 1992-03-05 | 1995-03-21 | Han Yang Chemical Corp. | Bipolar electrolyzer |
HU213001B (en) * | 1992-04-10 | 1997-01-28 | Tavkoezlesi Innovacios Rt | Process for obtaining tissue-protective deposit on implants prepared from titanium and/or titanium-base microalloy |
GB9211402D0 (en) * | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5429895A (en) * | 1994-10-13 | 1995-07-04 | Motorola, Inc. | Nickel alloy electrodes for electrochemical devices |
US5476589A (en) * | 1995-03-10 | 1995-12-19 | W. L. Gore & Associates, Inc. | Porpous PTFE film and a manufacturing method therefor |
-
1997
- 1997-01-06 US US08/779,304 patent/US5914026A/en not_active Expired - Lifetime
- 1997-12-31 WO PCT/US1997/024119 patent/WO1998030891A1/en not_active Application Discontinuation
- 1997-12-31 CA CA002276069A patent/CA2276069C/en not_active Expired - Fee Related
- 1997-12-31 AU AU59045/98A patent/AU734003B2/en not_active Ceased
- 1997-12-31 EP EP97954646A patent/EP1021706A4/en not_active Withdrawn
- 1997-12-31 JP JP53094598A patent/JP3950174B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3979274A (en) | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4073713A (en) | 1975-09-24 | 1978-02-14 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4484987A (en) * | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4941201A (en) | 1985-01-13 | 1990-07-10 | Abbott Laboratories | Electronic data storage and retrieval apparatus and method |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4945125A (en) | 1987-01-05 | 1990-07-31 | Tetratec Corporation | Process of producing a fibrillated semi-interpenetrating polymer network of polytetrafluoroethylene and silicone elastomer and shaped products thereof |
US4832009A (en) | 1987-12-23 | 1989-05-23 | Bio Med Sciences, Inc. | Semi-interpenetrating network polymer backsheet bandage |
US5260701A (en) | 1990-01-19 | 1993-11-09 | Societe Bertin & Cie | Bidirectional inductive transmission of data with slave station supplied by the master |
US5372133A (en) * | 1992-02-05 | 1994-12-13 | N.V. Nederlandsche Apparatenfabriek Nedap | Implantable biomedical sensor device, suitable in particular for measuring the concentration of glucose |
US5469846A (en) * | 1992-10-19 | 1995-11-28 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
Non-Patent Citations (2)
Title |
---|
HIGSON ET AL.: "Glucose Oxidase Enzyme Electrode: Relation Between Inner Membrane Permeability and Substrate Response", ANALYTICA CHIMICA ACTA, vol. 276, 1993, pages 335 - 340, XP001021390 * |
See also references of EP1021706A4 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000059373A1 (en) * | 1999-04-07 | 2000-10-12 | Spectrx, Inc. | Assay device for measuring characteristics of a fluid on a continual basis |
US9597027B2 (en) | 2003-07-25 | 2017-03-21 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8909314B2 (en) | 2003-07-25 | 2014-12-09 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US10610140B2 (en) | 2003-07-25 | 2020-04-07 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US9993186B2 (en) | 2003-07-25 | 2018-06-12 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US9237864B2 (en) | 2009-07-02 | 2016-01-19 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
US9517025B2 (en) | 2009-07-02 | 2016-12-13 | Dexcom, Inc. | Analyte sensor with increased reference capacity |
US9763608B2 (en) | 2009-07-02 | 2017-09-19 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
US9351677B2 (en) | 2009-07-02 | 2016-05-31 | Dexcom, Inc. | Analyte sensor with increased reference capacity |
US9131885B2 (en) | 2009-07-02 | 2015-09-15 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
US9357951B2 (en) | 2009-09-30 | 2016-06-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10667733B2 (en) | 2009-09-30 | 2020-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10835161B2 (en) | 2009-09-30 | 2020-11-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11937927B2 (en) | 2009-09-30 | 2024-03-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
Also Published As
Publication number | Publication date |
---|---|
US5914026A (en) | 1999-06-22 |
JP3950174B2 (en) | 2007-07-25 |
CA2276069C (en) | 2005-02-22 |
AU5904598A (en) | 1998-08-03 |
EP1021706A1 (en) | 2000-07-26 |
AU734003B2 (en) | 2001-05-31 |
JP2001508176A (en) | 2001-06-19 |
EP1021706A4 (en) | 2001-07-18 |
CA2276069A1 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5914026A (en) | Implantable sensor employing an auxiliary electrode | |
EP0948743B1 (en) | Glucose sensor | |
US9804114B2 (en) | Sensor head for use with implantable devices | |
US5746898A (en) | Electrochemical-enzymatic sensor | |
CA2045616C (en) | Enzyme electrochemical sensor electrode and method of making it | |
US4484987A (en) | Method and membrane applicable to implantable sensor | |
US4650547A (en) | Method and membrane applicable to implantable sensor | |
CA2079748C (en) | Hydrophilic polyurethane membranes for electrochemical glucose sensors | |
EP1214586B1 (en) | Implantable glucose sensor | |
EP0204468A2 (en) | Membrane | |
JPH04233446A (en) | Electrochemical enzyme sensor | |
CZ192894A3 (en) | Homogeneous membrane for a biological sensing element | |
Kyröläinen et al. | Blood compatibility and extended linearity of lactate enzyme electrode using poly (vinyl chloride) outer membranes | |
Atanasov et al. | Glucose biosensor based on oxygen electrode. Part I: silastic coated polycarbonate membranes for biosensor application | |
JPH085601A (en) | Enzyme sensor and its production | |
JPH03158750A (en) | Enzyme sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP SI |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 59045/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: CA Ref document number: 2276069 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997954646 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2276069 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 530945 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954646 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 59045/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954646 Country of ref document: EP |